SFSandy Hwang Fang

Sandy Hwang Fang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sandy Hwang Fang has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification of Factors That Determine Adherence for Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer

    by Cynthia Araradian, Emmett Hunnicutt, Siting Chen, Shawna Rivedal, Shelby Willis, Maura Walsh, Vassiliki Liana Tsikitis, Sandy Hwang Fang

    Background: Locally advanced rectal cancer (LARC) treatment has shifted from the utilization of neoadjuvant chemoradiation (NACRT), followed by total mesorectal excision (TME) and adjuvant chemotherapy (AC) to the implementation of total neoadjuvant therapy (TNT). This transition was influenced by data from multiple studies reporting suboptimal compliance rates to adjuvant chemotherapy. As a result, a paradigm shift to TNT occurred, consisting of chemoradiation with chemotherapy, based on the RAPIDO and PRODIGE-23 studies. Methods: Following IRB approval, a single-institution retrospective chart review was conducted at a tertiary care academic institution for patients with LARC. Demographic, clinical, and treatment data were collected using REDCap. Patients were excluded if under 18 years of age, pregnant, or had stage 1 or metastatic rectal cancer. The primary objective was to evaluate TNT adherence; secondary objectives assessed adherence associations with demographic and clinical variables. Results: Two hundred twenty-nine patients with rectal cancer were initially included in the database, including 153 patients with LARC from 2019 to 2024. One hundred twenty-seven patients underwent TNT with an adherence rate of 87.5%. Statistically significant variables that contributed to adherence include male gender (p = 0.04) and non-use of recreational drugs (p = 0.04). Conclusions: This is the first real-world study assessing TNT adherence. The observed 87.5% adherence rate represents a significant improvement over historical data in which patients were treated with NACRT/TME/AC. Statistically significant variables that contributed to TNT adherence included male gender and non-use of recreational drugs. These factors may provide insight into gender differences and behavioral patterns that put patients in an at-risk category for non-adherence.

  • Expert Commentary on Tumor Deposits in Colon Cancer

    by Sandy H Fang, Sandy H.

    An abstract is unavailable. This article is available as a PDF only.

  • Open Access

    A Systematic Review Defining Early Anal Squamous Cell Carcinoma and Identifying Treatment

    by Cynthia Araradian, Mariah R. Erlick, Emmett Hunnicutt, J. Michael Berry-Lawhorn, Emily B. Rivet, Rebekka Duhen, Joseph Terlizzi, Tamzin Cuming, Sandy H. Fang

    Background: Anal cancer screening has allowed for the diagnosis of early-stage anal cancers; however, guidelines for the treatment of early anal cancers remain mixed given the scarcity of clinical trials and data. Management ranges from chemoradiation therapy to local surgical excision. Methods: This paper’s objective is to clarify the definition of early anal cancer and its management. Approval for this systematic review was obtained through PROSPERO [CRD42022304327]. Three independent reviewers screened the studies and performed data analysis, with conflicts resolved by a fourth reviewer. All information is presented according to the Preferred Reporting Item for Systematic Reviews and Meta-Analysis (PRISMA). The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) criteria were used to assess the certainty of the evidence. Results: The MEDLINE, EMBASE and Cochrane databases were queried with 628 articles screened. A total of 15 articles were selected for inclusion. Early anal cancer was most often defined as T1-2N0M0 anal cancer but also included Superficially Invasive Squamous Cell Carcinoma (SISCCA). There were various treatments assessed for outcomes including local excision, chemoradiation, and radiation. The studies reported overall survival, cancer-specific survival, recurrence-free survival, and/or colostomy-free survival, leading to significant heterogeneity amongst the studies. No meta-analysis was possible. Conclusions: Poor-quality studies exist for the evaluation of the most effective treatment modality for early anal cancer. Surgical excision alone with adequate margins has equivocal results, but data is poor. Chemoradiation is successful but may be overtreatment. Randomized controlled studies are needed, as screening will result in earlier anal cancer diagnoses.

  • Open Access

    A phase I study of intra-anal artesunate (suppositories) to treat anal high-grade squamous intraepithelial lesions

    by Sandy Hwang Fang, Mihaela Plesa, Evie H Carchman, Nicole A Cowell, Emily Staudt, Kyleigh Ann Twaroski, Ulrike K Buchwald, Cornelia L Trimble

    Ablation or surgical excision is the typical treatment of anal high-grade squamous intraepithelial lesions (HSIL). Recurrences are common due to the persistence of underlying human papillomavirus (HPV) infection. Additional well-tolerated and effective non-surgical options for HPV-associated anal disease are needed. This 3+3 dose escalation Phase I clinical trial evaluated the safety and tolerability of artesunate suppositories in the treatment of patients with biopsy-proven HSIL. The maximal tolerated dose was 400 mg, administered in 3 cycles. All adverse events associated with the use 200- and 400-mg artesunate suppositories were Grade 1. At the 600-mg dose, patients experienced clinically significant nausea. Artesunate suppositories are a safe treatment option for anal HSIL.


  • Open Access

    Recanalization of a complete coloanal anastomotic obstruction using a combined antegrade-retrograde rendezvous technique

    by Saowanee Ngamruengphong, Sonmoon Mohapatra, Thomas M. Runge, Eduardo Paredes, Sandy H. Fang

    A 66-year-old man with a history of lower rectal adenocarcinoma and robotic-assisted low anterior resection with creation of a diverting ileostomy, presented with complete stenosis of the coloanal anastomosis ([Fig. 1 a]). Rendezvous recanalization of the coloanal obstruction was planned ([Video 1]). Video 1 Recanalization of a complete coloanal anastomotic obstruction using a combined antegrade-retrograde rendezvous technique. A pediatric colonoscope was advanced through the ileostomy toward the distal colon where complete obstruction was identified at the coloanal anastomosis ([Fig. 1 b]). As the colonoscope could not be advanced to the blind end, the blunt end of an injection needle was used to push at the blind end to facilitate identification of the puncture site ([Fig. 2 a]). Using transillumination and digital palpation, the coloanal anastomosis was punctured from the anal side using a trocar ([Fig. 2 b]). A 0.035-inch Jagwire (Boston Scientific, Marlborough, Massachusetts, USA) was advanced through the trocar and captured using a snare. The guidewire was pulled out and both ends of the guidewire were captured. The coloanal stricture was dilated using a controlled radial expansion balloon ([Fig. 3 a]). An 18 × 153-mm esophageal fully covered metal stent was advanced from the anal side and deployed across the coloanal stricture ([Fig. 3 b]). The stent was secured with two 2-0 silk sutures. To maintain patency of the anastomosis in the event of stent migration, a colonic decompression tube was advanced over the guidewire and both ends were sutured together. Computed tomography scan confirmed correct position of the stent ([Fig. 4]). Sigmoidoscopy was performed at 4 weeks for stent removal. The anastomosis was patent and had healed ([Fig. 5]). Ileostomy reversal was successfully performed 5 days later. Rendezvous recanalization of complete coloanal obstruction is a potential alternative to revision surgery, which is difficult and has high morbidity. When endoscopic ultrasound-guided techniques for accessing the proximal colon are not possible, combination of transillumination and digital palpation is a viable option. Endoscopy_UCTN_Code_TTT_1AQ_2AF Publication Date: 27 February 2020 (online) © Georg Thieme Verlag KG Stuttgart · New York


  • Emergency department presentation, admission, and surgical intervention for colonic diverticulitis in the United States

    by Eric B. Schneider, Aparajita Singh, Jennifer Sung, Benjamin Hassid, Shalini Selvarajah, Sandy H. Fang, Jonathan E. Efron, Anne O. Lidor


  • Next Generation Sequencing of Circulating Tumor Cells Isolated from the Peripheral Blood of Patients with Gastrointestinal Cancer. Circle-1 Trial

    by K. Kato, H. Shoji, T. Kakizaki, K. Honda, A. Kakimoto, T. Sakuma, T. Yamada, S. Fang, A. Wu, C.T. Lim, et al.

    Aim: Monitoring of tumor biology provides pivotal information for suitable therapy. Circulating tumor cells (CTCs) released into the blood stream from primary tumor and metastases may reflect current tumor status. The ClearCell FX system (Clearbridge Biomedics, Singapore), which uses a label-free inertial microfluidics approach based on biomechanical properties, is able to capture CTCs independent of EpCAM expression. We investigated the tumor biology by performing genomic profiling of CTCs using next-generation sequencing (NGS). Methods: Patients with advanced gastric and colorectal cancer were enrolled in this study. We collected 10mL of blood from each patient. CTCs were extracted by using the Clearcell FX system. DNA was prepared immediately after isolation, after a week's culture with RepCellTM (CellSeed) which was a temperature-responsive cell cultureware. Whole genome amplification (WGA) was performed by using REPLI-g Single Cell Kit (Qiagen), and NGS was performed by using Ion Ampliseq (LifeTechnology). Cells were enumerated using cytokeratin staining and immunocytochemical analysis. At the same time, we prepared DNA not only from peripheral blood mononuclear cells but also from plasma (cell-free DNA). Results: 8 patients were enrolled; 6 had colorectal cancer and 2 had gastric cancer. Median of CTC count was 6/mL (ranges 3 to 14). On the other hand, the number of CTCs collected by CellSearch ranged from 0 to 1/7.5mL. In these 8 cases, either right after isolation or after 1 week of culture, DNA derived from CTCs was successfully prepared by WGA. NGS was successfully performed with WGA treated DNA from CTCs and related materials. Conclusions: By using ClearCell FX System's label-free technology, we were able to capture a larger number of CTCs from patients with gastric and colorectal cancer than with using the CellSearch system. NGS from CTCs and related materials can be performed successfully. Disclosure: A. Kakimoto: I am a employee of SRL Inc.; T. Sakuma: I am a employee of Mitsui Knowledge Industry Co and Ltd.; S. Fang: I am a employee of Clearbridge Accelarator; A. Wu: I am a employee of Clearbridge Bio Medics; C.T. Lim: I have stock of Clearbridge Biomedics Pte Ltd. All other authors have declared no conflicts of interest.


  • Expansion of a Cell Population Expressing Stem Cell Markers in Parathyroid Glands From Patients With Hyperparathyroidism

    by Sandy H. Fang, Julie A. Guidroz, Yunxia O'Malley, Geeta Lal, Sonia L. Sugg, James R. Howe, Chris S. Jensen, Ronald J. Weigel

    Objective: We sought to examine abnormal parathyroid glands for the presence of stem cells. Summary Background Data: Cancer stem cells have been identified in cancers from a variety of tissues as a CD44+/CD24− cell population. We hypothesize that stem cells (SC) may also be involved in the pathogenesis of benign clonal expansion characteristic of hyperparathyroidism (HPT). Methods: Under institutional review board approval, parathyroid tissue was obtained from 20 patients with HPT and analyzed by fluorescence-activated cell sorting (FACS) for the CD44+/CD24− cell population. Immunohistochemistry (IHC) with CD44 antibody was correlated with FACS results. Results: Parathyroid tissue was obtained for FACS analysis from 25 enlarged parathyroid glands from 20 patients, 17 with primary HPT, and 3 with secondary HPT. The average percent of SC defined as CD44+/CD24− population was 10.93% for enlarged parathyroid glands. IHC using CD44 antibody was performed on 27 abnormal parathyroid glands and 7 normal parathyroid gland biopsies from the same patients. Although IHC was not as sensitive as FACS, comparison of IHC and FACS results for 24 abnormal glands gave a correlation coefficient of 0.52, which was statistically significant (P = 0.01, Spearman rank). By IHC, 13 of 27 abnormal glands stained 1+ to 3+ (average, 0.93) compared with no CD44 staining in normal glands, which was statistically different (mean IHC of 0 vs. 0.93, P = 0.03, Wilcoxon). Conclusions: These novel findings demonstrate expansion of a resident cell population that expresses SC markers in abnormal parathyroid glands from patients with HPT. Our results suggest that clonal expansion of a resident SC population occurs in the pathogenesis not only of cancer, but also in benign parathyroid tumors occurring in HPT.